TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03088280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: reduced dose (3mg/Kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: reduced dose (3mg/Kg)
Study: NCT00038467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
Study: NCT00996008

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.5 g (w/w) placebo cream applied to each target lesion twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT 327
Description: 0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
Study: NCT06541925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection with the needle-free (NF) system
Description: Before the injection procedure, the children were demonstrated the popping sound produced by device to prevent reflex reactions, and they informed that they would feel as if their gum were punched. The NF injection device was prepared according to the manufacturer's instructions, placed in full contact with the buccal mucosa and a pre-withdrawn dose of 0.1 ml was applied to the buccal region for topical purposes by the pushing the top of the device. After 10-15 seconds, the same procedure was repeated with withdrawn dose of 0.3 ml. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Injection with the traditional method (TM)
Description: The depth of penetration was only a few millimeters and 0.3ml of anesthetic solution was deposited. After 5 min the treatment commenced, and the children were instructed to raise their hand if they experienced pain during the procedure. Each time the child indicated pain, in accordance with the same protocol an additional 0.3 ml of anesthetic solution was administered, until the sufficient anesthetic effect was obtained and the final amount of anesthetic solution were recorded. Precautions were taken to prevent tissue ballooning.
Study: NCT02467972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-eat frozen soups added unripe banana flour
Description: Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready-to-eat frozen soups added maltodextrin
Description: Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-eat frozen soups added inulin
Description: Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-eat frozen soups added nisin
Description: Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
Study: NCT03962218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aquatic physiotherapy
Description: specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: aquatic physiotherapy
Description: specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
Study: NCT03296215

Intervention type: OTHER
Intervention: Observational
Description: To determine different patterns of admission and their Outcome
Study: NCT04101721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Administered IVT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser photocoagulation
Description: Transpupillary conventional laser will be administered according to standard local procedures.
Study: NCT03956901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pvi guided fluid management
Description: GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pvi guided fluid management
Description: GDFM Group: 500 ml bolus crystalloid after~2 ml \\ kg crystalloid infusion to be started~If PVI \<13 MAP is \<65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI \<13 MAP\> 65 mmHg to continue fluid infusion If PVI\> 13 MAP \<65 mmHg, 250 ml bolus crystalloid \\ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI \<13.~PVI\> 13 MAP \<65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl \<13.
Study: NCT02531698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 Vaccine
Description: 1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Licensed pediatric hepatits A vaccine
Description: 1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline
Description: Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
Study: NCT01164137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation
Description: A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
Study: NCT04218344

Intervention type: OTHER
Intervention: 60mls of blood donated for research analysis
Description: All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.

Intervention type: OTHER
Intervention: 60mls of blood donated for research analysis
Description: All patients presenting with a possible Acute Coronary Syndrome will be invited to donate 60 mls of blood at the time of their angiogram.
Study: NCT02255773

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized Tasks
Description: 3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
Study: NCT00799812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).
Description: 3 swabsticks topically applied at the same time to intact skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG 2% w/v & IPA 70% v/v swab applied sequentially
Description: Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous CHG 4% w/v applied according to mfr's directions
Description: Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile swabstick with sterile water (3 @ once)
Description: 3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile swabstick with sterile water (one-at-a-time)
Description: Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
Study: NCT02154516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ODH Hip System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ODH Hip System
Study: NCT01515202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2 mg, Once daily, 14 days
Study: NCT02255773

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized Tasks
Description: 3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
Study: NCT01515202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 12 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 25 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 15 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-823778
Description: Capsules, Oral, 0 mg, Once daily, 14 days
Study: NCT00308113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0/75 mg/kg/day.
Study: NCT01713478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
Study: NCT00308113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0/75 mg/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: serum levels of greater or equal to 2.5 micrograms/mL.
Study: NCT01713478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography
Description: The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
Study: NCT00308113

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: serum levels of greater or equal to 2.5 micrograms/mL.
Study: NCT03071341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181
Description: Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
Study: NCT05308342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplantation of human UC-MSCs into ovaries of POI patients
Description: UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hormone replacement treatment
Description: Routine estrogen progesterone replacement periodic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormone replacement treatment
Description: Routine estrogen progesterone replacement periodic therapy
Study: NCT00377195

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Field Radiotherapy
Description: The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days.
Study: NCT03396783

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test
Description: during the visit, nurse will make a blood test for biological and immunological analysis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: during the visit, nurse will make a blood test for biological and immunological analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromyogram and walk test
Description: during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
Study: NCT02809495

Intervention type: OTHER
Intervention: use of app in smartphone
Study: NCT03286426

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pictor
Description: The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
Study: NCT03208387

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion tensor imaging (DTI)
Description: DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
Study: NCT01170767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
Study: NCT01170767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
Study: NCT01518465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03369314

Intervention type: DRUG
Intervention: octaplasLG®
Description: Data will be collected in all patients who have received at least one infusion of octaplasLG®
Study: NCT01596699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
Study: NCT01991678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 145 mg/m2 NKTR 102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg/m2 NKTR 102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/m2 NKTR 102
Study: NCT01811329

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy fat + MFGM
Description: BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palm fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm fat + MFGM
Description: BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
Study: NCT00295529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention
Description: Educational materials available at end of study
Study: NCT04497571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric osteotomy.
Description: Implants placed using the ultrasonic technique.
Study: NCT03582917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alphacalcidol
Description: Alphacalcidol 0,5mg tablet
Study: NCT04497571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drilling
Description: Implants placed using drilling technique
Study: NCT03208387

Intervention type: BEHAVIORAL
Intervention: Grooved Pegboard
Description: This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.

Intervention type: BEHAVIORAL
Intervention: Grooved Pegboard
Description: This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.

Intervention type: BEHAVIORAL
Intervention: PedsQL Multidimensional Fatigue Scale
Description: Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).

Intervention type: BEHAVIORAL
Intervention: PedsQL Multidimensional Fatigue Scale
Description: Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).

Intervention type: BEHAVIORAL
Intervention: PedsQL Multidimensional Fatigue Scale
Description: Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
Study: NCT03025620

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rapeseed oil
Description: Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil
Description: Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
Study: NCT02066558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon monoxide
Description: carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02520531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scorpio PS (posterior stable)
Description: Implantation of total knee prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scorpio NRG PS
Description: Implantation of total knee prosthesis